MGMT and neoplasm: O6-methylguanine-DNA-methyltransferase methylation status as a host-specific rather than tumour-specific condition explains why MGMT promoter methylation of the tumour was highly associated with TMZ tolerance in patients requiring more dose reductions or discontinuations.